Intellia Therapeutics has announced that its experimental gene-editing drug reduced the number of swelling attacks in patients with a rare genetic disease in a large trial, driving its shares up 3%.
The findings led Intellia to begin a rolling submission of its data on the gene therapy as it seeks approval from the U.S. Food and Drug Administration next year, it said.
Intellia, which was founded by CRISPR inventor and 2020 Nobel Prize winner Jennifer Doudna, was trialling the therapy, lonvoguran ziclumeran, for hereditary angioedema (HAE), an inherited condition that causes swelling attacks.
The drug is based on CRISPR gene editing, which uses “scissors” to cut out damaged segments of genes, allowing them to be switched off or replaced with new segments of normal DNA. For lonvo-z, it does this by silencing a gene responsible for the protein kallikrein, which causes swelling attacks.
In the 80-patient trial, a single injection of the therapy cut swelling attacks by 87%, compared to a placebo over six months, achieving the It also kept 62% of patients free of attacks compared with 11% in the placebo group for the duration.
Intellia chief financial officer Edward Dulac told an analyst call that lonvo-z was likely to be priced higher than current HAE therapies, but that it would not want to price the drug too high and risk angering payers. Existing therapies for the disease include Ionis Pharma’s Dawnzera and Takeda Pharmaceutical’s Takhzyro.
Intellia estimates that HAE occurs in 1:50,000 people. Cantor analyst Steve Seedhouse said lonvo-z “will likely be a niche product,” and noted the risk of a possible “black box” label for fatal liver toxicity in a separate Intellia CRISPR drug. Adverse events were mainly infusion reactions such as headache and fatigue, and were all mild or moderate, it said.
Intellia has reported encouraging results from a late-stage clinical trial, where Intellia’s investigational gene therapy demonstrated a significant reduction in swelling attacks in patients with a rare genetic condition, widely associated with hereditary angioedema (HAE).
The findings highlight Intellia’s growing leadership in CRISPR-based therapies, positioning Intellia as a major innovator in genetic medicine.
Clinical Results from Intellia Study
The late-stage study conducted by Intellia showed that patients receiving the gene therapy experienced a substantial decrease in the frequency of swelling attacks, a hallmark symptom of HAE.
Key outcomes from Intellia’s trial include:
- Dramatic reduction in monthly swelling episodes
- Durable response following a single treatment dose
- Favorable safety and tolerability profile
- Reduced reliance on chronic preventative therapies
These results reinforce the potential of Intellia’s therapy to provide long-term disease control.
Expanded Clinical Insights from the Late-Stage Study
The late-stage trial provides deeper insight into how gene-editing therapies are beginning to shift expectations in rare disease treatment. Patients treated in the study showed not only fewer swelling attacks, but in some cases near-complete elimination of episodes over extended follow-up periods. This level of durability is rarely seen with conventional therapies, which typically require ongoing dosing.
Importantly, the therapeutic effect appeared consistent across different patient subgroups, suggesting broad applicability regardless of baseline disease severity.
Durability and One-Time Treatment Potential
A standout feature of this therapy is its potential as a single-dose, long-lasting solution. Unlike traditional prophylactic treatments that must be administered regularly, gene-editing approaches aim to deliver sustained benefit after just one intervention.
Early long-term follow-up data suggests:
- Stable reduction in disease biomarkers over time
- Continued suppression of swelling episodes beyond initial treatment period
- Minimal need for rescue medications
If these results hold, it could significantly reduce treatment burden and healthcare costs over a patient’s lifetime.
Safety Profile and Monitoring
Safety remains a critical factor for gene-editing therapies, especially those involving permanent genetic changes. In this study, the treatment demonstrated a manageable safety profile, with most side effects being mild to moderate.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
